Stephen B. Howell, MD, presented “How to Use Natural Ligands to Kill Tumor Stem Cells” during the 34th International Prostate Cancer Update on February 12, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Howell, Stephen B. “How to Use Natural Ligands to Kill Tumor Stem Cells.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/how-to-use-natural-ligands-to-kill-tumor-stem-cells/
How to Use Natural Ligands to Kill Tumor Stem Cells – Summary
Stephen B. Howell, MD, explores the possibility of using Cancer Stem Cell-Targeted Therapy to fight cancerous tumors and prevent recurrence. He begins with a review of the role of LGR receptors and RSPO ligands in active stem cells.
Dr. Howell then presents data from a trial demonstrating how a particular drug, FcF2-MMAE, can target cancerous tumor cells through a particular LGR receptor. He provides data on FcF2-MMAE’s promising pharmacokinetic and pharmaceutical properties.
Dr. Howell concludes by stating that the drug needs to be studied outside of an academic research environment. While most of the academic research has been done on the responsiveness of tumor stem cells in ovarian cancer, he anticipates that the FcF2-MMAE framework may have applications for prostate cancer tumors.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
